CDK4/6 inhibitors

Jul 17, 2026

Summary H2 2026 is expected to be a highly active FDA regulatory period, with decisions spanning oncology, nephrology, infectious diseases, neurology, hematology, and rare diseases, reflecting greater therapeutic diversity beyond oncology dominance. Key innovation trends include first- and best-in-class biol...

Jun 08, 2026

Summary HR+/HER2- breast cancer continues to represent a major target indication for SERDs, with approximately 481,000 cases reported in 2024 in the 7MM.  High-profile failures from Sanofi (amcenestrant) and a long list of early-stage candidates such as GDC-029, AZD9496, GDC-0927, ZnC5, LSZ-102, brinale...

Dec 09, 2024

In the rapidly evolving landscape of cancer therapy, one class of drugs is making waves for its game-changing impact: CDK4/6 inhibitors. These revolutionary agents are rewriting the narrative for treating cancers driven by uncontrolled cell division, particularly hormone receptor-positive, HER2-negative breast canc...

Nov 11, 2024

In the rapidly evolving field of oncology, novel CDK7 inhibitors are emerging as game-changers, challenging the status quo of cancer treatment. By specifically targeting CDK7, these innovative therapies not only halt cancer cell proliferation but also enhance the effectiveness of existing treatments. With the abili...

Nov 04, 2024

Cyclin-dependent kinase 7 (CDK7) belongs to the CDK family of serine/threonine protein kinases and plays a crucial role in regulating the cell cycle and mRNA transcription. It is often overexpressed in various cancers, making it a promising target for cancer treatment due to its involvement in both transcription an...